Related Experiment Video
Updated: Oct 4, 2025

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
HCV neutralization goes elite
Mattia Bonsignori1, Joseph Marcotrigiano2
1Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
A vaccine remains the most promising option to eradicate HCV. In this issue of Immunity, Weber et al. identified HCV elite neutralizers, isolated exceptionally potent and broad VH1-69 CD81-binding site neutralizing antibodies that used a shared mode of antigen recognition, and developed a computational approach that predicted mutations relevant to gain-of-function for this bnAb class, which can inform immunogen designs.

